151 results on '"Gill, Harinder"'
Search Results
2. In the Pipeline: Emerging Therapy for MDS and MDS/MPN
3. Modern Classification of Acute and Chronic Leukemias: Integrating Biology, Clinicopathologic Features, and Genomics
4. Molecular Landscape and Personalized Prognostic Prediction of MPNs
5. In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia
6. Management of Relapsed Acute Promyelocytic Leukemia and the Role of Hematopoietic Stem Cell Transplantation
7. Prognostic Indicators in MDS and CMML
8. Clonal Hematopoiesis and Its Functional Implications in MDS/AML
9. Role of IDH1/IDH2 Inhibitors in AML
10. Treatment Algorithm for Primary and Secondary Myelofibrosis
11. Frontline Management of Acute Promyelocytic Leukemia
12. In the Pipeline: Emerging Therapy for CML
13. Management of Relapsed or Refractory AML
14. Prognostic Models for Primary and Secondary Myelofibrosis
15. Eosinophilic Disorders and Systemic Mastocytosis
16. Next-Generation FLT3 Inhibitors for the Treatment of FLT3-Positive AML
17. In the Pipeline—Emerging Therapy for ALL
18. In the Pipeline: Emerging Therapy for Classical Ph-Negative MPNs
19. VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
20. Prioritising the psychosocial needs of young oncology patients: a call for comprehensive care
21. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
22. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
23. Bomedemstat as an investigative treatment for myeloproliferative neoplasms
24. Rethinking Palliative Care in Psychiatry
25. POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
26. MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
27. Editorial: Acute promyelocytic leukemia - towards a chemotherapy-free approach to cure in all patients, Volume II
28. Rheumatology and palliative care: needs and opportunities
29. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
30. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation
31. Complexities in delivering end-of-life care in accordance with patient desires that have been documented
32. Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107
33. Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond
34. Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis
35. A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
36. A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
37. Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients
38. MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
39. Poster: MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
40. The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
41. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia
42. Perspective of palliative care in radiation-oncology
43. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis
44. Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases
45. Epidemiology and outcomes of acute promyelocytic leukaemia in the era of all-trans retinoic acid (ATRA) chemotherapy and arsenic trioxide plus ATRA: a retrospective analysis
46. Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study
47. Genome-wide sequencing and the clinical diagnosis of genetic disease: The CAUSES study
48. Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents
49. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991-2021
50. MO846: Temporal Evolution of Humoral Response in Haemodialysis Patients Vaccinated With Two Doses of CHADOX1-S Vaccine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.